Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus

被引：21

作者：

Low, DE

Kreiswirth, BN

Weiss, K

Willey, BM

机构：

[1] Mt Sinai Hosp, Dept Microbiol, Toronto Med Labs, Toronto, ON M5G 1X5, Canada

[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[3] Publ Hlth Res Inst, New York, NY USA

[4] Univ Montreal, Hop Maison Neuve Rosemont, Montreal, PQ, Canada

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2002年 / 20卷 / 03期

关键词：

methicillin-resistant Staphylococcus aureus; GAR-936; linezolid; quinupristin/dalfopristin;

D O I：

10.1016/S0924-8579(02)00132-2

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The comparative in vitro activity of GAR-936 and 12 other drugs against 602 North American isolates of methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus was determined. The GAR-936 MICs ranged from 0.06 to 1.0 mg/l. The MIC(50)s and MIC(90)s were 0.12 and 0.25 mg/l for MSSA and 0.25 and 0.5 mg/l for MRSA. (C) 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.

引用

收藏

页码：220 / 222

页数：3

相关论文

共 14 条

[1]

[Anonymous], PERF STAND ANT SUSC

[2] In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].

Boucher, HW ;

Wennersten, CB ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229

[3] GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae:: preliminary guidelines and interpretive criteria [J].

Deshpande, LM ;

Gales, AC ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) :29-35

[4]

Edlund C, 2000, CLIN MICROBIOL INFEC, V6, P158

[5] Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci [J].

Hoellman, DB ;

Pankuch, GA ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1085-1088

[6] Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? [J].

Livermore, DM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :347-350

[7] Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis [J].

Murphy, TM ;

Deitz, JM ;

Petersen, PJ ;

Mikels, SM ;

Weiss, WJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3022-3027

[8]

National Committee for Clinical Laboratory Standards, 2000, METH DIL ANT SUSC TE

[9] Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus [J].

O'Neill, AJ ;

Cove, JH ;

Chopra, I .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :647-650

[10] In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae [J].

Patel, R ;

Rouse, MS ;

Piper, KE ;

Steckelberg, JM .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :177-179